About encorafinib
BRAF kinase inhibitor
Used for
- With cetuximab for BRAF V600E-mutant metastatic colorectal cancer after prior treatment.
- With binimetinib for BRAF V600E-mutant unresectable or metastatic melanoma.
Usual adult dose
Melanoma: 450 mg once daily with binimetinib. Colorectal cancer: 300 mg once daily with cetuximab.
Common side effects
- Fatigue
- Nausea and vomiting
- Diarrhea
- Joint or muscle pain
Important warnings
- May cause new skin cancers; skin examinations are recommended.
- Can cause eye problems, bleeding, heart problems, or liver injury.
- May cause fetal harm; effective contraception is recommended during treatment.
- Follow the prescribed combination and monitoring schedule; dosing differs by cancer type.
Pregnancy
May cause fetal harm. Human pregnancy data are limited.
Breastfeeding
Breastfeeding is not recommended during treatment and for three weeks after the last dose.
Interactions
- Strong or moderate CYP3A4 inhibitors can increase encorafenib exposure.
- Strong or moderate CYP3A4 inducers can reduce its effectiveness.
- Encorafenib can affect medicines metabolized by CYP3A4 or CYP2B6.
- It can reduce the effectiveness of hormonal contraceptives.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.